Cargando…
Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia
MGS0274 besylate is an ester‐based lipophilic prodrug of a metabotropic glutamate (mGlu) 2 and mGlu3 receptor agonist MGS0008 and being developed for the treatment of schizophrenia. We investigated the disposition of these compounds in rats and monkeys and in vitro metabolism in humans to evaluate w...
Autores principales: | Kinoshita, Kohnosuke, Ochi, Motoki, Iwata, Katsuya, Fukasawa, Misako, Yamaguchi, Jun‐ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743422/ https://www.ncbi.nlm.nih.gov/pubmed/31523433 http://dx.doi.org/10.1002/prp2.520 |
Ejemplares similares
-
Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects
por: Watanabe, Mai, et al.
Publicado: (2020) -
The cancellation of mass gatherings (MGs)? Decision making in the time of COVID-19
por: Ahmed, Qanta A., et al.
Publicado: (2020) -
Mgs1 function at G-quadruplex structures during DNA replication
por: Paeschke, Katrin, et al.
Publicado: (2020) -
Ketoprofeno a 100,75 y 50 mgs. para analgesia postoperatoria
por: González Aguilar, Lorena
Publicado: (1999) -
DNA flap creation by the RarA/MgsA protein of Escherichia coli
por: Stanage, Tyler H., et al.
Publicado: (2017)